Elan

Elan acknowledges Royalty’s proposal

Monday, February 25, 2013 10:57 AM

The board of Elan, a biotechnology company based in Ireland, has acknowledged the announcement by Royalty Management regarding an indicative, conditional, proposal which may or may not lead to an offer being made for the entire issued share capital of Elan.

More... »

Biogen Idec acquires full rights of Tysabri from Elan

Wednesday, February 6, 2013 11:41 AM

Biogen Idec, an independent biotechnology company, has agreed to purchase biotech Elan’s full strategic, commercial and decision-making rights to Tysabri.

More... »

Elan sells remaining stake in Alkermes

Friday, February 1, 2013 01:43 PM

Following the close of trading today, Elan’s wholly-owned subsidiary, Elan Science Three, agreed to sell, on customary terms, all of its remaining 7,750,000 ordinary shares of Alkermes through Jefferies & Company pursuant to Rule 144 under the U.S. Securities Act of 1933. The sale is expected to close on February 6, 2013.

More... »

Elan completes demerger of Prothena

Friday, December 21, 2012 02:40 PM

Dublin-based Elan has completed the separation of a substantial portion of its drug discovery business (the Prothena Business) into a new independent, publicly traded company, Prothena. Incorporated in Ireland, Prothena commenced trading on the NASDAQ Global Market as of Dec. 21.

More... »

Elan announces spin-off of discovery science with Neotope Biosciences

Monday, August 13, 2012 11:50 AM

The board of directors of Elan, an Irish neuroscience-focused biotech, has approved the spin-off of discovery science with the separation of Neotope Biosciences from Elan.

More... »

North Shore-LIJ Health System joins Cleveland Clinic’s Innovation Alliance

Tuesday, February 28, 2012 06:11 AM

North Shore-LIJ Health System, the second-largest nonprofit in the U.S. secular healthcare system, has joined Cleveland Clinic’s Innovation Alliance program to enhance the discovery, development, deployment and commercialization of new technologies.

More... »

Intellect Neurosciences to appeal in European patent proceedings

Wednesday, February 15, 2012 03:30 PM

Intellect Neurosciences, a biopharmaceutical company focused on disease-modifying therapeutic agents for Alzheimer's disease, submitted a statement setting out its grounds for appealing the European Patent Office's (EPO) preliminary decision to revoke the company's Antisenilin (bapineuzumab) patents.

More... »

Cleveland BioLabs announces management reorganization

Friday, February 10, 2012 11:39 AM

Cleveland BioLabs, a drug discovery and development company, has made a number of changes in corporate management responsibilities.

More... »

FDA approves label change for Tysabri

Tuesday, January 24, 2012 10:48 AM

The FDA has approved a product label change for Biogen Idec/Elan’s Tysabri that will help enable individual benefit-risk assessment for patients with multiple sclerosis (MS).

More... »

University of Cambridge, Elan launch research center

Monday, November 28, 2011 03:21 PM

The University of Cambridge and Elan have launched The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at the University of Cambridge, England. The Cambridge-Elan Centre will provide an interdisciplinary environment uniquely positioned for delivering translational research focused on innovative therapies for Alzheimer's and Parkinson's diseases. This ten-year agreement paves the way for a long-term collaboration between Elan and the University of Cambridge.

More... »